The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | C | Cardiovascular system | |
| 2 | C02 | Antihypertensives | |
| 3 | C02K | Other antihypertensives | |
| 4 | C02KN | Other antihypertensives |
| Code | Title | |
|---|---|---|
| C02KN01 |
| Active Ingredient | Description | |
|---|---|---|
| Aprocitentan |
Aprocitentan is an ERA that inhibits the binding of endothelin (ET)-1 to ETA and ETB receptors. ET-1, via its receptors (ETA and ETB), mediates a variety of deleterious effects such as vasoconstriction, fibrosis, cell proliferation, and inflammation. In hypertension, ET-1 can cause endothelial dysfunction, vascular hypertrophy and remodeling, sympathetic activation, and increased aldosterone synthesis. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| TRYVIO Film-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
